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Non-infected central venous
catheters in hemodialysis patients
are not associated with
inflammation
To the Editor: A recent study, conducted by Goldstein et al.,
showed that the serum C-reactive protein (CRP) level of
patients who underwent hemodialysis (HD) with non-
infected central venous catheters (CVCs) was higher than
that of those who underwent HD via native arteriovenous
ﬁstulas (AVFs). In these patients, betadine solution was used
for exit-site care.1 Our aim was to evaluate the changes in the
serum CRP levels of HD patients who underwent dialysis via
native AVF (AVF-1), then via temporary tunneled CVC for
AVF dysfunction, and again via AVF (AVF-2). Eighteen
tunneled jugular CVCs in 18 HD patients were included.
Heparin lock and alcoholic-chlorhexidine solution was used
for exit-site disinfection. The mean CRP values during the
three periods were not different (Figure 1). A cross-sectional
study in 225 HD patients in December 2008 showed that
the median serum CRP levels of patients using AVF (89%)
and CVC (11%) were 7 (IQR 3–20) and 10 (3–21)mg/l,
respectively (NS). We have previously shown that the
incidence of catheter-related bacteremia decreased from
1.1 to 0.2/1000 catheter day during 1994–1997 and
2004–2007 when betadine was substituted with alcohol-
chlorhexidine solution.2 As this solution was more efﬁcient
than betadine in our hands, we hypothesized that the
difference in the ﬁndings reported in the two studies may
be attributed to the differences in the solution used. However,
to conﬁrm this hypothesis, a controlled study should be
conducted in order to compare these two protocols.
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catheters are associated with increased inflammation compared to
arteriovenous fistulas. Kidney Int 2009; 76: 1063–1069.
2. Jean G, Vanel T, Bresson E et al. An efficient strategy to decrease the
central venous catheter-related adverse events rate in haemodialysis
patients. Nephrol Therap 2009; 5: 280–286.
Guillaume Jean1, Thierry Vanel1 and Charles Chazot1
1Centre de Rein Artificiel, Service de Ne´phrologie He´modialyse, Tassin, France
Correspondence: Guillaume Jean, Centre de Rein Artificiel, Service de
Ne´phrologie He´modialyse, 42 Avenue du 8 Mai 1945, Tassin 69160, France.
E-mail: guillaume-jean-crat@wanadoo.fr
Kidney International (2010) 78, 709; doi:10.1038/ki.2010.239
The Authors Reply: We thank Dr Jean and colleagues1 for
their interest in our work.2 They question our ﬁndings of
increased C-reactive protein (CRP) using a non-infected
hemodialysis catheter. The ﬁndings of their study contradict
ours, and all previous studies, which reported an increase in
the inﬂammation associated with catheter use compared with
arteriovenous ﬁstulas.3–5 One study4 assessed 128 prevalent
chronic hemodialysis patients (2405 CRP measurements),
ﬁnding catheter presence was independently associated with
CRP level, and catheter placement or removal was associated
with an increase or improvement in CRP level, respectively.
Our study was the ﬁrst to evaluate non-infected catheters as a
sole mechanism for inﬂammation, adjusted for potential
confounding variables. The authors hypothesize the reason
that they did not observe increased CRP in catheter patients
was because of different antiseptic use for exit site care. They
propose a controlled study to directly address the potential for
inﬂammation induction between two protocols. The informa-
tion accumulated in the literature makes such a study
unnecessary and potentially unethical. Even though the
authors’ hypothesis is correct, we are concerned their letter
implies catheter use is acceptable based on their small study.
Our group, and others, believes catheters should be avoided in
dialysis patients. In addition to inﬂammation, the increase
in morbidity and mortality associated with catheters is well
established.2 A recent paper ‘Ethical and Legal Obligation to
Avoid Long-Term Tunneled Catheter Access’ reminds us the
ﬁrst duty of a physician is to do no harm.6 In our opinion the
continued catheter use is harmful.
1. Jean G, Vanel T, Chazot C. Non-infected central venous catheters in
hemodialysis patients are not associated with inflammation. Kidney Int
2010; 78: 709.
2. Goldstein SL, Ikizler TA, Zappitelli M et al. Non-infected hemodialysis
catheters are associated with increased inflammation compared to
arteriovenous fistulas. Kidney Int 2009; 76: 1063–1069.
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Figure 1 |CRP evolution. Changes in serum C-reactive protein
(CRP) levels of patients undergoing dialysis first via arteriovenous
fistula (AVF-1), then via central venous catheter (CVC), and again
via arteriovenous fistula (AVF-2). Median (interquartile range)
values are shown.
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Importance of 3 h when dialyzing
daily
To the Editor: Brunelli et al.,1 by using a rigorous statistical
analysis, conﬁrm previous information on the association
between short dialysis time and increased mortality. Recent
studies could shed light on the mechanistic reasons for this
association. In a prospective, non-randomized study of
77 dialysis patients, subjects who underwent 3 h daily dialysis
(3 h, six times weekly) had a signiﬁcant decrease in left
ventricular mass, phosphorus and inﬂammation compared
with those who underwent conventional dialysis.2,3 Thus, as
Brunelli et al. rightly predict, a longer dialysis time is
beneﬁcial in improving the markers associated with increased
mortality. Unfortunately, many nephrologists and the dialysis
industry as a whole are still using the Kt/V urea kinetics over
dialysis time in determining dialysis prescriptions.
Even the current NIH-sponsored daily dialysis trial is
using the urea kinetics-based approach for treatment
times in the in-center daily dialysis arm. It is predicted
that they will fall below that 3-h treatment time mark that
we have advocated.3 Shorter dialysis times (less than 3 h),
even when prescribed 6 days a week, do not adequately
control serum phosphorus, an important marker of dialysis
mortality.3
Lastly, one disturbing ﬁnding in the study is the percentage
(61.5%) of patients initiating dialysis through a catheter. In
addition to increased infections, catheters are independently
associated with increased inﬂammation even when they are
not infected.4
Thus, two simple therapeutic maneuvers—increased dia-
lysis time and frequency to improve serum phosphorus
control and avoiding dialysis catheters—can improve survival.
1. Brunelli SM, Chertow GM, Ankers ED et al. Shorter dialysis times are
associated with higher mortality among incident hemodialysis patients.
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The Authors Reply: As Drs Ayus and Achinger rightfully
note,1 longer dialytic session length is associated with
improved patient survival even when measures of urea
kinetics conform to the current standards of care. We agree
that this effect may be mediated in part through improved
phosphate homeostasis. Consequently we estimated the
marginal structural hazards ratio for death by comparing
session lengths o240min with those X240min among
subgroups of patients with baseline serum phosphate p5.5
and 45.5mg/dl: 1.42 (1.22–1.65) and 1.38 (1.03–1.85),
respectively. That the estimates were similar in both serum
phosphorus subgroups may indicate that derangements in
phosphate metabolism exceed those reﬂected by serum
phosphate concentrations, such as consequent elevations in
serum FGF-23, which are themselves associated with
increased mortality.2
Amelioration of left ventricular hypertrophy may underlie
the association between dialytic session length and survival,
and may itself derive from more gradual ultraﬁltration rates
and consistent attainment of dry weight enabled by longer
dialysis. We believe that the ‘adequacy’ of ultraﬁltration
warrants further study.
We agree that our ﬁndings are consistent with the notion
that more dialysis is better, and this may bear relevance for
other (for example, short daily) dialytic paradigms. However,
we urge caution with extrapolation beyond the context of
thrice-weekly dialysis settings, given the absence of otherwise
treated patients in the cohort we examined.
Finally, we echo the authors’ concern that catheter use is
epidemic, noting that more contemporary data from United
States Renal Data Service indicate a catheter prevalence of
83.5% among incident hemodialysis patients.3
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